| Subject: | FDA Requires Addition of Boxed Warning to Metoclopramide |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Fri, 27 Feb 2009 - 02:00 pm |
| The Food and Drug Administration (FDA) has notified healthcare professionals that manufacturers of metoclopramide, a drug used to treat gastrointestinal disorders, must add a Boxed Warning to their drug labels about the risk of its long-term or high-dose use. Chronic use of metoclopramide has been linked to tardive dyskinesia even after the drugs are no longer taken. The symptoms are rarely reversible and there is no known treatment. Metoclopramide is available in a variety of... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! provides immediate online healthcare compliance validation to our healthcare users. When faced with dramatic reductions in healthcare dollars, StayAlert! focuses on those processes that can save the most time and money. By automating labor-intensive activities, StayAlert! almost instantly produces a positive impact on the healthcare user's bottom line. The policies alone included with the StayAlert! notices can save you $65,000 or more in labor costs each year. Organizations will realize dramatic cost savings through elimination of labor intensity, increased productivity with the benefit of ensuring regulatory compliance. StayAlert! is the service-oriented supplier of health care's compliance needs. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|